Bioventus (BVS)

• Market cap: $620M
• 1 day: 2.40%
• 5 days: -0.74%
• 1 month: -7.68%
• 3 months: -11.85%
• 6 months: -20.53%
• Year to date: -11.85%
• 1 year: 79.50%
• 5 years: -51.22%
• 10 years: -51.22%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Employees: 930

9.37 USD

+0.22

2.40%

At close Apr 1, 4:00 PM EDT

Pre-market

9.00

-0.37

3.95%

1 day

2.40%

5 days

-0.74%

1 month

-7.68%

3 months

-11.85%

6 months

-20.53%

Year to date

-11.85%

1 year

79.50%

5 years

-51.22%

10 years

-51.22%

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

249% more call options, than puts

Call options by funds: $2.71M | Put options by funds: $775K

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

9% more funds holding

Funds holding: 138 [Q3] → 150 (+12) [Q4]

0.31% more ownership

Funds ownership: 69.33% [Q3] → 69.64% (+0.31%) [Q4]

12% less capital invested

Capital invested by funds: $540M [Q3] → $478M (-$62.3M) [Q4]

14% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 51

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 60% upside
• Avg. target: $15 60% upside
• High target: $15 60% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin 21% 1-year accuracy 3 / 14 met price target

60% upside $15

Buy Maintained

17 Mar 2025